Brief: UAB And Mereo Biopharma Group Announce Positive Top-Line Results From “Costa” A Phase 1B/2 Trial Of Alvelestat (Mph966) In Hospitalized Patients With Covid-19 Respiratory Disease
22/12/2021 12:25
Dec 22 (Reuters) - Mereo Biopharma Group PLC MAH0y.F :
* UAB AND MEREO ANNOUNCE POSITIVE TOP-LINE RESULTS FROM
“COSTA” A
PHASE 1B/2 TRIAL OF ALVELESTAT (MPH966) IN HOSPITALIZED PATIENTS
WITH COVID-19 RESPIRATORY DISEASE
* MEREO BIOPHARMA GROUP PLC - ALVELESTAT REPORTED SAFE AND
WELL-TOLERATED IN PATIENTS WITH COVID-19
Source text for Eikon: ID:nGNX5Vvhyr
Further company coverage: MAH0y.F
((reuters.briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand